Comparative Pharmacology
Head-to-head clinical analysis: E BASE versus ERYTHROMYCIN STEARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E BASE versus ERYTHROMYCIN STEARATE.
E-BASE vs ERYTHROMYCIN STEARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
E-BASE is a proton pump inhibitor that irreversibly inhibits the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, suppressing gastric acid secretion.
Erythromycin is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptides.
25 mg orally once daily.
250-500 mg orally every 6 hours or 500-1000 mg orally every 12 hours; maximum 4 g/day.
None Documented
None Documented
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; may be prolonged in renal impairment.
1.4-2 hours in adults with normal renal function; prolonged to 5-6 hours in anuria; unchanged in hepatic impairment.
Renal excretion of unchanged drug accounts for approximately 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Primarily excreted in bile as active drug; about 2-5% excreted renally as unchanged drug. Up to 15% excreted in feces.
Category C
Category A/B
Macrolide Antibiotic
Macrolide Antibiotic